Bortezomib
- Generic Name
- Bortezomib
- Brand Names
- Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25BN4O4
- CAS Number
- 179324-69-7
- Unique Ingredient Identifier
- 69G8BD63PP
- Background
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.
Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.
- Indication
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
- Associated Conditions
- Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
- Associated Therapies
- -
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
- Conditions
- Interventions
- Drug: PrednisoneDrug: VincristineDrug: DaunorubicinDrug: PegaspargaseDrug: Erwinase®Drug: CyclophosphamideDrug: CytarabineDrug: MercaptopurineDrug: DasatinibDrug: MethotrexateDrug: BlinatumomabDrug: DexamethasoneDrug: RuxolitinibDrug: ThioguanineDrug: BortezomibDrug: Asparaginase Erwinia chrysanthemi (recombinant)-rywnDrug: Calaspargase PegolDrug: DoxorubicinDrug: EtoposideDrug: NelarabineDrug: ClofarabineDrug: VorinostatDrug: Idarubicin
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 790
- Registration Number
- NCT03117751
- Locations
- 🇺🇸
Children's Hospital of Michigan, Detroit, Michigan, United States
🇺🇸St. Jude Affiliate Clinic - Novant Health Hemby Children's Hospital, Charlotte, North Carolina, United States
🇦🇺The Royal Children's Hospital Melbourne, Parkville, Victoria, Australia
Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide
- Conditions
- Interventions
- First Posted Date
- 2017-04-17
- Last Posted Date
- 2020-12-02
- Lead Sponsor
- PharmaMar
- Target Recruit Count
- 10
- Registration Number
- NCT03117361
- Locations
- 🇫🇷
CHRU de Lille - Hôpital Claude Huriez, Lille, France
🇫🇷Institut Gustave Roussy, Villejuif, France
🇮🇹Policlinico Vittorio Emanuele Hospital, Catania, Italy
Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2017-04-12
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 402
- Registration Number
- NCT03110562
- Locations
- 🇨🇦
Princess Margaret Cancer Research, Toronto, Ontario, Canada
🇺🇸Kaiser Permanente Hawaii, Honolulu, Hawaii, United States
🇺🇸Norton Cancer Institute, Louisville, Kentucky, United States
Treatment of Adult-Onset Immunodeficiency With Bortezomib
- First Posted Date
- 2017-04-06
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- Mahidol University
- Target Recruit Count
- 5
- Registration Number
- NCT03103555
- Locations
- 🇹🇭
Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell Lymphoma
- First Posted Date
- 2017-01-11
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- Tingbo Liu
- Target Recruit Count
- 50
- Registration Number
- NCT03016988
A Single-center Clinical Trial of Bortezomib in Management of Immune Thrombocytopenia (ITP)
- First Posted Date
- 2017-01-06
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Shandong University
- Target Recruit Count
- 20
- Registration Number
- NCT03013114
- Locations
- 🇨🇳
Shandong University Qilu hospital, Jinan, Shandong, China
2015-12: a Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- First Posted Date
- 2016-12-28
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 50
- Registration Number
- NCT03004287
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
2015-09: A Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy
- Conditions
- Interventions
- First Posted Date
- 2016-12-22
- Last Posted Date
- 2017-04-14
- Lead Sponsor
- University of Arkansas
- Registration Number
- NCT03000634
Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment
- Conditions
- Interventions
- First Posted Date
- 2016-11-30
- Last Posted Date
- 2022-05-31
- Lead Sponsor
- Universitätsklinikum Hamburg-Eppendorf
- Target Recruit Count
- 22
- Registration Number
- NCT02977494
- Locations
- 🇩🇪
Katholische Karl-Leisner Klinikum Goch, Goch, Germany
🇩🇪Charité Universitätsmedizin BerlinCampus Benjamin Franklin, Berlin, Germany
🇩🇪Asklepios Klinik Altona, Hamburg, Germany
Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA)
- Conditions
- Interventions
- First Posted Date
- 2016-11-04
- Last Posted Date
- 2018-03-29
- Lead Sponsor
- National University of Ireland, Galway, Ireland
- Target Recruit Count
- 18
- Registration Number
- NCT02955810
- Locations
- 🇮🇪
Galway University Hospital, Galway, Ireland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.